CPRX News and Press, Catalyst Pharmaceuticals Inc. From 09/29/22

CORAL GABLES, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announc...

Have you ever experienced sticker shock when looking at a stock? If so, it was probably for something like Berkshire Hathaway (NYSE: BRK.A) , with an eye-popping price of $419,020 per share. Thankfully, there are much cheaper companies to buy, and some of them might even grow a bit ...

Multiple insider sales have hurt commercial-stage biotech Catalyst Pharmaceuticals ( NASDAQ: CPRX ) as the company became a notable decliner in the pre-market trading Friday with a drop of ~7% . The sellers include CPRX, co-founder, President, and Chief Executive Patri...

Summary Catalyst Pharmaceuticals reached a 52-week high on September 13, 2022. Catalyst was recently added to the S&P SmallCap 600 Index. Revenue is ramping quickly but could flatten going into 2023. Catalyst Pharmaceuticals ( NASDAQ: CPRX ) specializes i...

Catalyst Pharmaceuticals Set to Join S&P SmallCap 600 Catalyst Pharmaceuticals Set to Join S&P SmallCap 600 PR Newswire NEW YORK , Sept. 12, 2022 /PRNewswire/ -- Catalyst Pharmaceuticals Inc. (NASD: CPRX) will replace Mantech International Cor...

Catalyst Pharmaceuticals ( NASDAQ: CPRX ) has jumped 8.6% after hours following word that the stock will join the S&P SmallCap 600 index . Catalyst is set to replace ManTech International ( MANT ) in the list. The Carlyle Group is nearing the close of its a...

Shares of rare disease specialist Catalyst Pharmaceuticals (NASDAQ: CPRX) jumped by a healthy 10.9% through the first days of trading this week, according to data from S&P Global Market Intelligence . The biotech's stock has been defying the 2022 bear market all year long. ...

CORAL GABLES, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced th...

The shares of Catalyst Pharmaceuticals ( NASDAQ: CPRX ) dropped ~8% in the morning hours Wednesday to record the biggest intraday loss in over three months after Roth Capital Partners downgraded the commercial stage biotech to Neutral from Buy. The analyst Scott Henry ...

CORAL GABLES, Fla., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announce...